|

Lisocabtagene maraleucel Clinical Trials

7 actively recruiting trials across 5 locations

▼ -1 trial since August 2026

Also known as: Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017 +4 more

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

  • Juno Therapeutics, Inc., a Bristol-Myers Squibb Company3
  • SWOG Cancer Research Network1
  • Lyell Immunopharma, Inc.1
  • Fred Hutchinson Cancer Center1
  • Bristol-Myers Squibb1

Indications

  • Cancer7
  • Non-hodgkin Lymphoma2
  • Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma1
  • Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma1
  • Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma1

Milwaukee, Wisconsin3 trials

A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Center for International Blood and Marrow Transplant Research (CIBMTR)

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Center for International Blood and Marrow Transplant Research (CIBMTR)

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

CIBMTR

Gilbert, Arizona1 trial

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Banner MD Anderson Cancer Center

Phase 3

Tucson, Arizona1 trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Banner University Medical Center - Tucson

Phase 2

Portland, Oregon1 trial

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Local Institution - 0016

Seattle, Washington1 trial

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.